Attendee search 

Leader in consensus forecast analysis of the biotech and pharma sector providing trusted insight into global performance to 2024.

Present Value specialise in acquisition, divestment, licensing, partnering and strategy in life science. Our experience is purely pharmaceutical and anyone who works on your prospective project will have worked in the industry for some time.  Of course, we also benefit hugely from an excellent network that has been built organically through our project work (a recent project may saw us liaising with more than one hundred companies across Europe as an example).

Recently celebrating over 10 years of success for our clients, Present Value was founded back in 2007. You can get a flavour of the types of projects and transactions we work on by looking at some of the cases histories on our website.  Alternatively, please see below for a synopsis...

1. Acquire - We will find you new targets:

·         It is difficult to find businesses or assets to acquire, especially the right shape and size for your business. We have a structured way of hunting for deals and maintain a database of potential sellers. We can be your extra set of eyes and ears out there.

2. Divest - You deserve the right value for your asset or company:

·         We would not call a company Present Value if we did not understand the equation. It is not just about an equation, it is about a thorough understanding of what drives the value in your business. We have developed an efficient process to gain you best value for your asset. You get on with running your business while we organise all the relevant documentation and deal with potential buyers.

3. Licensing - Take the essential route to pharmaceutical licensing:

·         We spend a lot of time at the pharmaceutical industry’s partnering meetings and have a good idea of what each company is looking for or what they might be offering. We tend to stick to branded innovative licensing.

4. Consulting - Expert analysis on every aspect in business of Life Science:

·         If you are struggling with something or looking to get some fresh ideas, we work on all sorts of business development projects and strategies. They are always about unlocking extra value and getting the best out of your assets.

All our projects are bespoke to you and should your project require more specialist corporate finance, regulatory or legal input we can cover that too and tend to put together a bespoke team of competent individuals or complimentary firms.

Our past and current clients range from individual entrepreneurs, family firms, country subsidiaries and global entities.  We are proud of our track record of repeat and continuing business from a number of our clients, many of whom have taken us with them when they move to a new company.

If you would like to have a chat about how we can help, please call on +44 (0) 1892 825663 or if you at any PLG, EMIG, Bio Europe event, we’re likely to be there too.

We’re generally useful to know and we look forward to hearing from you.

Both Andrew Dean and Adam Minshall are available for meetings in Montreux.  Alternatively, why not just find either of us for an informal chat.

George Health Enterprises is the commercial arm of The George Institute for Global Health. George Health Medicines (a wholly owned subsidiary of GHE)  is focussed on the late stage development and key territory registration of pharmaceutical products which have resulted from The George Institute's ground-breaking research into the treatment of non-communicable diseases. George Health Medicines is seeking appropriate commercial partners globally for the medicines which it developes. The short term pipeline includes innovative medicines for the prophylaxis of cardiovascular disease and for the primary treatment of hypertension and Type II diabetes.

Silence Therapeutics is a leading RNAi company, developing highly innovative medicines with life-saving potential for patients with serious and rare diseases, based upon its proprietary technology platform in GalNAc conjugated siRNA.

The Company is in a strong position to maximise the potential of its IP and technology through collaborations and the advancement of internal programmes toward the clinic. Silence’s lead candidate SLN124 will move into clinical development in the coming year.

Company Description

Napp is part of a privately owned global network of independent associated companies. In Europe, Mundipharma and Napp have sales revenues of over $1bn combined.

We are an asset led, highly entrepreneurial and commercially minded business that is focussed on providing innovative medicines to UK patients across all parts of the NHS. We are ambitious to be a leading partnership selling organisation; creating strong and effective partnerships with commercial partners, healthcare providers and patients.

Structured in Business Units around our four commercial platforms of Primary Care, Specialty Care, Biosimilars and Branded Generics, we are able to make fast decisions and focus on the right products in the right areas.

Qdem, our branded generics house is a wholly owned subsidiary of Napp. Qdem has a team of 8 dedicated KAMs who cover the whole of the UK. We have had great success in gaining and maintaining market share with our branded generics Butec®, Longtec® and Shortec®.

Our other leading brands at Napp include Invokana® for Type II diabetes, Flutiform® for asthma and Remsima®, Truxima® and Herzuma® (biosimilars of infliximab, rituximab and trastuzumab).

We offer

Napp has exceptionally capable marketing, sales and market access matrix teams, which effectively build and grow originator products in competitive indication areas, and enjoy an excellent reputation in the NHS and with GPs and UK KOLs. Mundipharma has both a heritage and reputation for excellence in pharmaceutical marketing and sales around the world, and an excellent reputation with healthcare practitioners throughout our region.

We have the support and remit to grow quickly our Qdem UK generics business through the in-licensing and acquisition of assets. Our Qdem marketing and sales team consists of originator salespeople from within and outside of the Napp Pharmaceuticals business with superb payer, formulary and healthcare practitioner contacts, and has excellent experience for the launch of both complex and value added branded generics in the UK.

We are interested in:

We are looking for dossiers and supply across all therapy areas (but particularly respiratory, urology, CNS & gastroenterology) for the following:

Value add generics, with novel dose forms or strengths

Generic drug delivery devices

Other complex delivery forms

Delayed or complex release forms across all therapy areas

Napp is keen to explore partnership opportunities for NCEs, biologics, biosimilars, orphan medicines and generics.

We are not interested in

Immediate release generics.

Hospital tender only generics.

API. CRO, CSO or CMO services.